Immunicum AB
Immunicum hires Lise-Lotte Hallbäck as new CFO
Immunicum AB 13.07.2015 08:30 Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Gothenburg, Sweden, 2015-07-13 08:30 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) strengthens its organization with the recruitment of Lise-Lotte Hallbäck as CFO. Lise-Lotte Hallbäck will assume the position on October 1st and most recently served as Head of the Gothenburg office at Visma Services AB. She has extensive experience in leading positions in accounting and financial management of internationally operating companies and has also worked as an authorized accountant. 'We are very pleased to strengthen our organization with Lise-Lotte, whom I had the privilege to get to know during the time she spent at her former employer. She is thus well versed in our business', says Jamal El-Mosleh, CEO of Immunicum. Lise-Lotte Hallbäck will replace Per-Olof Gunnesson, the Company's current CFO, in the management team. Per-Olof Gunnesson, formerly a member of the Board of the Company, will continue to be linked to Immunicum as a consultant, focusing primarily on contractual issues. 'I'm really looking forward to taking the role as Immunicum's CFO. Immunicum is an exciting company with good prospects. With my background and expertise, I think there is a lot I can bring to the organization with regards to financial processes and other issues related to business development', says Lise-Lotte Hallbäck. Hallbäck has a Bachelor of Science in Business Administration and Economics from the School of Economics at Växjö University. For further information, please contact: Jamal El-Mosleh, CEO, Immunicum Phone: +46 (0) 31 41 50 52 jamal.el-mosleh@immunicum.com The Company's Certified Adviser is Redeye AB Phone: +46 (0) 8 545 013 31. www.redeye.se About Immunicum AB (publ) Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the Company's most advanced project - INTUVAX(R) against renal cancer - has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer. www.immunicum.com News Source: NASDAQ OMX 13.07.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Immunicum AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0005003654 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden